Ipratropium
- Generic Name
- Ipratropium
- Brand Names
- Atrovent, Combivent, Ipravent
- Drug Type
- Small Molecule
- Chemical Formula
- C20H30NO3
- CAS Number
- 60205-81-4
- Unique Ingredient Identifier
- GR88G0I6UL
- Background
Ipratropium is a quaternary ammonium derivative of atropine that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption.
...
- Indication
Inhaled ipratropium is indicated in combination with inhaled beta-agonist systemic corticosteroids for the management of severe exacerbations of asthma flares requiring treatment.
Asthma exacerbations are characterized by a progressive increase in one or more of asthma symptoms accompanied by a decrease in expiratory flow.
...
- Associated Conditions
- Acute Exacerbation of Asthma, Asthma, Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD), Nasal Congestion Associated With the Common Cold, Non-Allergic Rhinitis, Perennial Allergic Rhinitis (PAR), Rhinitis
- Associated Therapies
- -
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift
FDA expands DUPIXENT use for COPD, offering new treatment options for patients. COPD affects 44 million in 7MM, with cases expected to rise. DUPIXENT targets IL-4 and IL-13 pathways, reducing exacerbations and improving lung function.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath